keyword
MENU ▼
Read by QxMD icon Read
search

braf thyroid

keyword
https://www.readbyqxmd.com/read/29144823/the-relationship-of-braf-v600e-mutation-status-to-fdg-pet-ct-avidity-in-thyroid-cancer-a-review-and-meta-analysis
#1
Prasanna Santhanam, Rodhan Khthir, Lilja B Solnes, Paul W Ladenson
OBJECTIVES: Papillary thyroid cancers harboring BRAF (V600E) gene mutation have been shown to exhibit aggressive tumor behaviors and higher risks of recurrence and disease-specific death. In this systematic review and meta-analysis, we examine and report published evidence related to the accuracy of FDG-PET-CT in detection of residual disease in patients' with BRAF (V600E) mutated thyroid cancer. METHODS: We extracted data from PUBMED/MEDLINE and EMBASE from January, 1995 to March, 2017...
November 16, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29144541/genetic-landscape-of-papillary-thyroid-carcinoma-in-the-chinese-population
#2
Jialong Liang, Wanshi Cai, Dongdong Feng, Huajing Teng, Fengbiao Mao, Yi Jiang, Shanshan Hu, Xianfeng Li, Yujie Zhang, Baoguo Liu, Zhong Sheng Sun
Improvement in the clinical outcome of human cancers requires characterization of genetic alterations underlying their pathogenesis. Large-scale genomic and transcriptomic characterization of papillary thyroid carcinomas (PTCs) in Western populations has revealed multiple oncogenic drivers which are essential for understanding pathogenic mechanisms of this disease; while so far, the genetic landscape in Chinese patients with PTC remains uncharacterized. Here, we conducted a largescale genetic analysis of PTCs from patients in China to determine the mutational landscape of this cancer...
November 16, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/29134959/targeting-ret-driven-cancers-lessons-from-evolving-preclinical-and-clinical-landscapes
#3
REVIEW
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET rearrangements and mutations have since been identified as actionable drivers of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers. Nevertheless, response rates to RET-directed therapy are modest compared with those achieved using targeted therapies matched to other oncogenic drivers of solid tumours, such as sensitizing EGFR or BRAF(V600E) mutations, or ALK or ROS1 rearrangements...
November 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29133385/targeted-next-generation-sequencing-of-cancer-genes-in-poorly-differentiated-thyroid-cancer
#4
Tiemo S Gerber, Arno Schad, Nils Hartmann, Erik Springer, Ulrich Zechner, Thomas J Musholt
Poorly differentiated thyroid carcinoma (PDTC) is a rare malignancy with higher mortality than well-differentiated thyroid carcinoma. The histological diagnosis can be difficult as well as the therapy. Improved diagnosis and new targeted therapies require knowledge of DNA sequence changes in cancer-relevant genes. The TruSeq Amplicon Cancer Panel was used to screen cancer genomes from 25 PDTC patients for somatic single nucleotide variants in 48 genes known to represent mutational hotspots. A total of 4490 variants were found in 23 tissue samples of PDTC...
November 13, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/29132392/false-negative-braf-v600e-mutation-results-on-fine-needle-aspiration-cytology-of-papillary-thyroid-carcinoma
#5
Se Hyun Paek, Byung Seup Kim, Kyung Ho Kang, Hee Sung Kim
BACKGROUND: The BRAF V600E mutation is highly specific for papillary thyroid carcinoma (PTC). A test for this mutation can increase the diagnostic accuracy of fine-needle aspiration cytology (FNAC), but a considerably high false-negative rate for the BRAF V600E mutation on FNAC has been reported. In this study, we investigated the risk factors associated with false-negative BRAF V600E mutation results on FNAC. METHODS: BRAF V600E mutation results of 221 PTC nodules between December 2011 and June 2013 were retrospectively reviewed...
November 13, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29128185/correct-extent-of-thyroidectomy-is-poorly-predicted-preoperatively-by-the-guidelines-of-the-american-thyroid-association-for-low-and-intermediate-risk-thyroid-cancers
#6
Mashaal Dhir, Kelly L McCoy, N Paul Ohori, Cameron D Adkisson, Shane O LeBeau, Sally E Carty, Linwah Yip
BACKGROUND: Recent guidelines from the American Thyroid Association recommend thyroid lobectomy for intrathyroidal differentiated thyroid cancers <4 cm. Our aim was to examine histology from patients with cytologic results that were positive or suspicious for malignancy to assess the extent of initial thyroidectomy based on criteria from the 2015 American Thyroid Association guidelines. METHODS: We studied consecutive patients who had either a positive or suspicious for malignancy cytologic diagnosis and under prior American Thyroid Association guidelines underwent initial total thyroidectomy ± lymphadenectomy...
November 8, 2017: Surgery
https://www.readbyqxmd.com/read/29127087/dabrafenib-plus-trametinib-is-active-in-braf-v600e-anaplastic-thyroid-cancer
#7
(no author information available yet)
Dual BRAF/MEK inhibition achieves responses in 69% of BRAFV(600E) anaplastic thyroid cancers (ATC).
November 10, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29117154/brafv600e-and-ret-ptc-promote-proliferation-and-migration-of-papillary-thyroid-carcinoma-cells-in-vitro-by-regulating-nuclear-factor-%C3%AE%C2%BAb
#8
Dehua Zhou, Zhou Li, Xuefeng Bai
BACKGROUND Papillary thyroid carcinoma (PTC) is associated with mutations of BRAFV600E and RET/PTC and high levels of expression of nuclear factor-κB (NF-κB). However, few studies have focused on the association between NF-κB expression and mutations in BRAFV600E and RET/PTC, especially regarding PTC cell proliferation and migration. The aim of this in vitro study was to investigate the effect of BRAFV600E or RET/PTC on NF-κB expression, cell proliferation and cell migration in four established PTC cell lines...
November 8, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29115628/aberrant-hypermethylation-of-the-hoxd10-gene-in-papillary-thyroid-cancer-with-brafv600e-mutation
#9
Yi-Ming Cao, Jun Gu, Yan-Shu Zhang, Wen-Jun Wei, Ning Qu, Duo Wen, Tian Liao, Rong-Liang Shi, Ling Zhang, Qing-Hai Ji, Yu Wang, Guo-Hua Sun, Yang-Xing Zhao, Yuan-Jin Wang, Jian Yu, Yong-Xue Zhu
Epigenetic abnormalities as well as genetic abnormalities may play a vital role in the tumorigenesis of papillary thyroid cancer (PTC). The present study aimed to analyze the function and methylation status of the HOXD10 gene in PTC and aimed to identify relationships between HOXD10 methylation, HOXD10 expression, BRAF mutation and clinicopathological characteristics of PTC. A total of 152 PTC patients were enrolled in the present study. The methylation status of the HOXD10 promoter was analyzed by quantitative methylation-specific polymerase chain reaction (Q-MSP)...
October 25, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29113311/the-anti-apoptotic-bag3-protein-is-involved-in-braf-inhibitor-resistance-in-melanoma-cells
#10
Luana Guerriero, Giuseppe Palmieri, Margot De Marco, Antonio Cossu, Paolo Remondelli, Mario Capunzo, Maria Caterina Turco, Alessandra Rosati
BAG3 protein, a member of BAG family of co-chaperones, has a pro-survival role in several tumour types. BAG3 anti-apoptotic properties rely on its characteristic to bind several intracellular partners, thereby modulating crucial events such as apoptosis, differentiation, cell motility, and autophagy. In human melanomas, BAG3 positivity is correlated with the aggressiveness of the tumour cells and can sustain IKK-γ levels, allowing a sustained activation of NF-κB. Furthermore, BAG3 is able to modulate BRAFV600E levels and activity in thyroid carcinomas...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108474/molecular-testing-for-oncogenic-gene-alterations-in-pediatric-thyroid-lesions
#11
Sogol Mostoufi-Moab, Emmanuel Labourier, Lisa Sullivan, Virginia A LiVolsi, Yimei Li, Rui Xiao, Sylvie Beaudenon-Huibregtse, Ken Kazahaya, N Scott Adzick, Zubair W Baloch, Andrew J Bauer
BACKGROUND: Thyroid nodules are less common in pediatric patients (≤18 years) than in adults. The Bethesda System for Reporting Thyroid Cytopathology allows for individual risk stratification, but a significant number of nodules are indeterminate. Incorporating gene mutation panels and gene expression classifiers may aid in pre-operative diagnosis. The overall aim of this study was to assess the prevalence of oncogene alterations in a representative pediatric population and across a broad-spectrum of thyroid tumor diagnoses...
November 6, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29099711/braf-antibody-expression-in-different-types-of-thyroid-nodular-lesions
#12
E Barabadze, V Munjishvili, G Burkadze
Major problems haunt the physicians who need to delineate the best management strategy for their patients with thyroid nodule is the identification of the most aggressive cases, especially among papillary thyroid cancers, which would benefit from more aggressive therapy and follow up. Beyond its strong correlation with PTC, the BRAF mutation is well described to associate with poor prognosis. The aim of our study was to identify BRAF antibody expression in different hystotypes of the thyroid nodules and assessment of it expression according to the tumor aggressiveness...
October 2017: Georgian Medical News
https://www.readbyqxmd.com/read/29094776/molecular-testing-of-braf-ras-and-tert-on-thyroid-fnas-with-indeterminate-cytology-improves-diagnostic-accuracy
#13
M Decaussin-Petrucci, F Descotes, L Depaepe, V Lapras, M-L Denier, F Borson-Chazot, J-C Lifante, J Lopez
OBJECTIVE: Liquid-based (LB)-FNA is widely recognized as a reliable diagnostic method to evaluate thyroid nodules. However, up to 30% of LB-FNA remain indeterminate according to the Bethesda system. Use of molecular biomarkers has been recommended to improve its pathological accuracy but implementation of these tests in clinical practice may be difficult. Here, we evaluated feasibility and performance of molecular profiling in routine practice by testing LB-FNA for BRAF, N/HRAS and TERT mutations...
November 2, 2017: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://www.readbyqxmd.com/read/29083503/risk-factors-stratifying-malignancy-of-nodules-in-contralateral-thyroid-lobe-in-patients-with-preoperative-ultrasound-indicated-unilateral-papillary-thyroid-carcinoma-a-retrospective-analysis-from-single-center
#14
Tian Lv, Changbin Zhu, Zhongming Di
OBJECTIVE: Papillary thyroid carcinoma (PTC) is the most common thyroid carcinoma with a favorable clinical outcome. For unilateral PTC patients with thyroid nodules in the contralateral lobes, the necessity of total thyroidectomy (TT) is still in doubt. In this study, we aimed to define clinical factors that could be indicators for malignancy in nodules in the contralateral thyroid lobe, which could aid the clinician in selecting the appropriate operation approach. DESIGN, PATIENTS AND MEASUREMENTS: This is a retrospective study from Jan 2014 to Dec 2016 conducted in Shanghai Ruijin Hospital...
October 30, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/29079175/aberrant-expression-of-cd20-in-thyroid-cancer-and-its-clinicopathologic-significance
#15
Andrey Bychkov, Chan Kwon Jung
CD20 is the first line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. Recently, aberrant CD20 expression has been described in a small series of papillary thyroid carcinomas (PTC). We aimed to evaluate CD20 immunoexpression and to perform clinicopathologic correlation in a large set of thyroid tumors, including a cohort of high-grade thyroid cancer. A total of 625 cases of thyroid tumor comprised tissue microarrays of 538 PTCs and 47 follicular adenomas, and whole-slide sections of 40 aggressive thyroid carcinomas (10 radioiodine-refractory PTCs, 8 poorly differentiated, 5 anaplastic and 17 medullary thyroid carcinomas) were immunostained with anti-CD20 monoclonal antibody...
October 24, 2017: Human Pathology
https://www.readbyqxmd.com/read/29072975/dabrafenib-and-trametinib-treatment-in-patients-with-locally-advanced-or-metastatic-braf-v600-mutant-anaplastic-thyroid-cancer
#16
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, Fatima Rangwala, Bhumsuk Keam
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E-mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. Methods In this phase II, open-label trial, patients with predefined BRAF V600E-mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death...
October 26, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29070763/the-synergic-effect-of-braf-v600e-mutation-and-multifocality-on-central-lymph-node-metastasis-in-unilateral-papillary-thyroid-carcinoma
#17
Hai-Jiang Qu, Xue-Yan Qu, Ze Hu, Yan Lin, Jun-Rong Wang, Chang-Fu Zheng, Zhuo Tan
The purpose of this study is to evaluate the potential synergic effect of BRAF(V600E) mutation and multifocality on central lymph nodes metastasis (CLNM) in the patients with unilateral papillary thyroid carcinoma (PTC). We enrolled 413 patients with unilateral PTCs who accepted prophylactic unilateral or bilateral central lymph node dissection (LND). Univariate and multivariate analyses were made to determine the association between related factors and CLNM. Then, all patients were divided into 4 groups based on their status of BRAF(V600E) mutation and multifocality...
October 26, 2017: Endocrine Journal
https://www.readbyqxmd.com/read/29067516/case-control-study-of-papillary-thyroid-carcinoma-on-urinary-and-dietary-iodine-status-in-south-korea
#18
Joon-Hyop Lee, Ra-Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su-Jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K Park
BACKGROUND: The association between iodine levels and the risk of papillary thyroid cancer (PTC) has been suggested, but not definitively established. This study is to compare the iodine status of a group of patients with PTC (with and without BRAF (V600E)) with that of a healthy population cohort. METHODS: A cohort of patients scheduled for thyroidectomy was enrolled, along with a community-based health-screening cohort with no known history of thyroid disease...
October 24, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/29046324/etv6-ntrk3-and-strn-alk-kinases-fusions-are-recurrent-events-in-papillary-thyroid-cancer-of-adult-population
#19
André U Bastos, Ana Carolina de Jesus, Janete Maria Cerutti
OBJECTIVE: PTC-specific analysis identified novel fusions involving RET, BRAF, NTRK1, NTRK3, AGK and ALK genes in adults and pediatric PTC. Although many novel fusions are PTC-specific event and, therefore, are ideal for diagnosis purposes, validation across additional and larger cohorts is essential for introducing these potential diagnostic or prognostic biomarkers into the clinical practice. As most of the BRAF, NTRK3 and ALK fusions were initially found in pediatric PTC or in more aggressive thyroid carcinomas, and there is a great disparity across population, in this study, we screened a large set of adult sporadic PTC cases for the most prevalent kinases fusion lately described in the TCGA...
October 18, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29043574/characterization-and-implications-of-thyroid-dysfunction-induced-by-immune-checkpoint-inhibitors-in-real-life-clinical-practice-a-long-term-prospective-study-from-a-referral-institution
#20
F Guaraldi, R La Selva, M T Samà, V D'Angelo, D Gori, P Fava, M T Fierro, P Savoia, E Arvat
PURPOSE: Autoimmune diseases are typically associated with immune checkpoints blockade. This study aims at assessing, in real-life clinical practice, the prevalence and impact of thyroid disorders induced by immune checkpoint inhibitors. METHODS: 52 patients (30 F; age 61 ± 13 years) with advanced melanoma treated with ipilimumab (3 mg/kg i.v./3 weeks; 4 doses) were included. For disease progression, 29 (16 F) of them received nivolumab (3 mg/kg i.v./2 weeks) or pembrolizumab (2 mg/kg i...
October 17, 2017: Journal of Endocrinological Investigation
keyword
keyword
17698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"